AIMS/HYPOTHESIS: To determine causes of weight gain during insulin therapy with and without metformin in Type II (non-insulin-dependent) diabetes mellitus. METHODS:Twenty-six patients with Type II diabetes (body mass index 28+/-1 kg/m2) were treated with insulin alone (n = 13) or insulin and with metformin (n = 13). Components of energy balance (basal metabolic rate, energy intake, glucosuria) were measured at 0 and 12 months. RESULTS:Glycaemic control improved similarly in patients using (HbA1c 10.5+/-0.3 vs 7.6+/-0.2%, p<0.001) and not using (10.2+/-0.3 vs 7.8+/-0.3%, p < 0.001) metformin. The metformin group required 47 % less insulin than the group not using metformin (p < 0.001). Body weight increased by 3.8+/-0.8 and 7.5+/-1.6 kg (p < 0.05), respectively. Basal metabolic rate and glucosuria were similar at 0 and 12 months in both groups but the metformin group decreased energy intake by 1.12+/-0.46 MJ/day, whereas it remained unchanged in the other group (0.15+/-0.42 MJ/day). Changes in body weight and glycaemia were statistically significant independent determinants of basal metabolic rate. Their change in opposite directions explained why basal metabolic rate remained unchanged. CONCLUSION/ INTERPRETATION:Improved glycaemia promotes weight gain by decreasing both basal metabolic rate and glucosuria. Use of metformin decreases weight gain by reducing energy intake and is therefore a useful adjunct to insulin therapy in patients with Type II diabetes.
RCT Entities:
AIMS/HYPOTHESIS: To determine causes of weight gain during insulin therapy with and without metformin in Type II (non-insulin-dependent) diabetes mellitus. METHODS: Twenty-six patients with Type II diabetes (body mass index 28+/-1 kg/m2) were treated with insulin alone (n = 13) or insulin and with metformin (n = 13). Components of energy balance (basal metabolic rate, energy intake, glucosuria) were measured at 0 and 12 months. RESULTS: Glycaemic control improved similarly in patients using (HbA1c 10.5+/-0.3 vs 7.6+/-0.2%, p<0.001) and not using (10.2+/-0.3 vs 7.8+/-0.3%, p < 0.001) metformin. The metformin group required 47 % less insulin than the group not using metformin (p < 0.001). Body weight increased by 3.8+/-0.8 and 7.5+/-1.6 kg (p < 0.05), respectively. Basal metabolic rate and glucosuria were similar at 0 and 12 months in both groups but the metformin group decreased energy intake by 1.12+/-0.46 MJ/day, whereas it remained unchanged in the other group (0.15+/-0.42 MJ/day). Changes in body weight and glycaemia were statistically significant independent determinants of basal metabolic rate. Their change in opposite directions explained why basal metabolic rate remained unchanged. CONCLUSION/ INTERPRETATION: Improved glycaemia promotes weight gain by decreasing both basal metabolic rate and glucosuria. Use of metformindecreases weight gain by reducing energy intake and is therefore a useful adjunct to insulin therapy in patients with Type II diabetes.
Authors: A Goday Arno; A Goday Arno; F Alvarez Guisasola; J Díez Espino; I Fernández Fernández; D Tórtola Graner; D Acosta Delgado; M Aguilar Diosdado; J Herrera Pombo; L Felipe Pallardo Journal: Aten Primaria Date: 2001-03-31 Impact factor: 1.137
Authors: Brice Emanuelli; Sara G Vienberg; Graham Smyth; Christine Cheng; Kristin I Stanford; Manimozhiyan Arumugam; Mervyn D Michael; Andrew C Adams; Alexei Kharitonenkov; C Ronald Kahn Journal: J Clin Invest Date: 2014-01-09 Impact factor: 14.808
Authors: Sabine Arnolds; Sibylle Dellweg; Janina Clair; Marie-Paule Dain; Michael A Nauck; Klaus Rave; Christoph Kapitza Journal: Diabetes Care Date: 2010-03-31 Impact factor: 17.152
Authors: John P H Wilding; Paul Norwood; Caroline T'joen; Arnaud Bastien; James F List; Fred T Fiedorek Journal: Diabetes Care Date: 2009-06-15 Impact factor: 19.112